Big pharma Bristol-Myers Squibb (BMY) reported good midstage trial results for its drug candidate Opdivo in advanced squamous-cell lung cancer, sending its stock up nearly 8% to a 13-year high in early trading in the stock market today. The company released the abstract summarizing its Friday presentation at the Chicago Multidisciplinary Symposium on Thoracic Oncology, describing results of the Checkmate-063 trial. The patients in the trial were
Big pharma Bristol-Myers Squibb (BMY) reported a quarter of shrinking sales and earnings that still beat analysts’ expectations, sending shares up 2% in early afternoon trading in the stock market today. Bristol-Myers’ Q3 earnings slipped 2% from the year-earlier quarter to 45 cents a share, beating estimates by 3 cents. Sales dropped 4% to $3.9 billion, though Bristol noted that excluding the diabetes business it sold off to AstraZeneca (AZN)
Big pharma Merck affirmed Wednesday that it’ll present much-anticipated data from its hepatitis C program at next month’s American Association for the Study of Liver Diseases Liver Meeting, but investors will have to wait till the meeting itself to find out the actual data. Bristol-Myers Squibb (BMY) was more forthcoming, but its results failed to ignite the stock. Merck (MRK) said that it will present data from its phase-two C-Swift trial, which